Document Detail


Long-term experience with pentosanpolysulfate in interstitial cystitis.
MedLine Citation:
PMID:  9510339     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: An oral preparation of pentosanpolysulfate sodium (PPS) was recently approved by the Food and Drug Administration for interstitial cystitis (IC). Previously published articles have documented improvement in symptoms in 28% to 63% of patients, but no long-term studies have been published. No unique characteristics except for Hunner's ulcer have been found in patients experiencing relief from PPS. We report our experience with PPS following patients up to 116 months and analyze baseline parameters in an attempt to characterize long-term responders. METHODS: Baseline and follow-up data from 97 patients with IC and enrolled in a compassionate use study with PPS at the University of Wisconsin from 1987 to 1995 are analyzed. Previous treatments had failed, and patients had to pay for PPS. Patients continuing treatment with PPS were monitored every 3 months with questionnaires and laboratory tests. In 1996 an update on medication and a questionnaire developed by the National Institutes of Health Interstitial Cystitis Database were sent to patients who had discontinued treatment. RESULTS: By the end of the study period 11 (11.3%) of the patients were still taking PPS, with 6 (6.2%) doing so continuously for more than 18 months. Three (3%) patients who discontinued PPS were in long-term remission. An additional 15% had remission for a substantial period. Except for a weak correlation between less constant pain (P = 0.0439), no correlations were found between baseline parameters and duration of treatment with PPS. CONCLUSIONS: On a long-term basis, between 6.2% and 18.7% of patients with IC benefit from PPS. The only baseline factor predicting response to PPS was less constant pain.
Authors:
J V Jepsen; M Sall; P R Rhodes; D Schmidt; E Messing; R C Bruskewitz
Related Documents :
8049889 - Nonsteroidal antiinflammatory drug-induced gastroduodenal lesions: prophylaxis and trea...
15086179 - Radiation-induced rectal ulcer--prognostic factors and medical treatment.
18638269 - Initial healing rates as predictive factors of venous ulcer healing: the use of a laser...
8018979 - Nizatidine in the treatment of acute gastric ulcer: a multicenter trial.
8568479 - Hereditary angio-oedema: new clinical observations and autoimmune screening, complement...
19212169 - Latest results (12-21 years) of a prospective randomized study comparing billroth ii an...
21997589 - Results obtained with a new superelastic nitinol stapes prosthesis in stapes surgery.
17132479 - Rectocele repair: a randomized trial of three surgical techniques including graft augme...
17377929 - Preoperative gastric emptying and patterns of reflux as predictors of outcome after lap...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Urology     Volume:  51     ISSN:  0090-4295     ISO Abbreviation:  Urology     Publication Date:  1998 Mar 
Date Detail:
Created Date:  1998-03-27     Completed Date:  1998-03-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  381-7     Citation Subset:  IM    
Affiliation:
Department of Surgery, University of Wisconsin, Madison Hospital and Clinics, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Cystitis, Interstitial / diagnosis,  drug therapy*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Pentosan Sulfuric Polyester / therapeutic use*
Questionnaires
Time Factors
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 37300-21-3/Pentosan Sulfuric Polyester
Comments/Corrections
Comment In:
Urology. 1999 Apr;53(4):863   [PMID:  10197877 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prostatitis: myths and realities.
Next Document:  Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untre...